There were 1,649 press releases posted in the last 24 hours and 401,734 in the last 365 days.

ELECTROCORE, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District for District of New Jersey on behalf of all investors that purchased electroCore,…

LEAD PLAINTIFF DEADLINE IS NOVEMBER 25, 2019

NEW YORK, Sept. 27, 2019 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP   announces that   a federal securities class action lawsuit has been filed in the United States District Court for the District of New Jersey on behalf of all investors that purchased electroCore, Inc. (NASDAQ: ECOR) (“Company”) securities between June 22, 2018 and September 25, 2019 (“the “Class Period”) and/or pursuant or traceable the company’s June 2018 initial public offering (“IPO”). 

Investors who purchased shares of electroCore, Inc. are urged to contact the firm immediately at classmember@whafh.com or (800) 575-0735 or (212) 545-4774. You may obtain additional information concerning the action on our website, www.whafh.com.

If you have incurred losses in the shares of electroCore, Inc., you may, no later than November 25, 2019, request that the Court appoint you lead plaintiff of the proposed class. Please contact Wolf Haldenstein to learn more about your rights as an investor  in  the  shares  of electroCore, Inc.   

## Follow the firm and learn about newly filed cases on Twitter and Facebook. ##

On June 21, 2018, electroCore completed its initial public offering (“IPO”) in which it sold 5.2 million shares at $15.00 per share. On May 14, 2019, the company announced that its first quarter 2019 financial results fell short of investors’ expectations, reporting $410,000 in net sales and an operating loss of $14.2 million.

On this news, the company’s  share price fell $1.58, or nearly 29%, to close at $3.75 per share on May 15, 2019.

Then, on September 25, 2019, the company revealed that the U.S. Food and Drug Administration (FDA) requested more information and analysis of clinical data for electroCore’s 510(k) submission, which seeks an expanded indication for the use of gammaCore, the Company’s treatment for pain associated with episodic cluster headache.

On this news, the company’s share price fell $0.79, or over 23%, to close at $2.57 per share on September 25, 2019.

Wolf Haldenstein has extensive experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country.  The firm has attorneys in various practice areas; and offices in New York, Chicago and San Diego.  The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major positions in complex securities multi-district and consolidated litigation.

If you wish to discuss this action or have any questions regarding your rights and interests in this case, please immediately contact Wolf Haldenstein by telephone at (800) 575-0735, via e-mail at classmember@whafh.com, or visit our website at www.whafh.com.

Contact:

Wolf Haldenstein Adler Freeman & Herz LLP
Kevin Cooper, Esq.
Gregory Stone, Director of Case and Financial Analysis
Email: gstone@whafh.com, kcooper@whafh.com or classmember@whafh.com
Tel: (800) 575-0735 or (212) 545-4774

Attorney Advertising. Prior results do not guarantee or predict a similar outcome.

Primary Logo